Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Benzimidazole derivatives and methods of use thereof

A compound and solvate technology, applied in the field of benzimidazole derivatives, can solve problems such as lactic acidosis, nausea and diarrhea

Inactive Publication Date: 2010-03-17
SCHERING AG
View PDF13 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these drugs can induce lactic acidosis, nausea, and diarrhea

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Benzimidazole derivatives and methods of use thereof
  • Benzimidazole derivatives and methods of use thereof
  • Benzimidazole derivatives and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0246] Preparation of Intermediate Compound A

[0247]

[0248] Synthesis of Step 1 Compound A1

[0249]

[0250] To a solution of 2-amino-4-picoline (10.81 g, 100 mmol) in t-butanol (250 mL) was added t-BOC anhydride (26.19 g, 120 mmol). The reaction mixture was stirred at 23°C for about 15 hours, then concentrated in vacuo. The obtained crude product oil was dry-loaded on a silica gel column, and subjected to flash chromatography (eluent: 30% hexane-CH 2 Cl 2 to 0-2% acetone-CH 2 Cl 2 ), yielding 15.25 g (73.32 mmol; 73%) of compound A1 as a white solid.

[0251] Synthesis of Step 2 Compound A2

[0252]

[0253] To a solution of compound A1 (35.96 g, 173 mmol) in THF (1.4 L) was added n-BuLi (1.4M in hexane, 272 ml, 381 mmol) portionwise at -78°C over 30 min. The reaction mixture was then allowed to warm slowly and stirred at 23°C for 2 hours, an orange precipitate formed. The mixture was then cooled back to -78°C and pre-dried oxygen (through a Drierite col...

Embodiment 2

[0263] Preparation of Intermediate Compound B

[0264]

[0265] Synthesis of step 1 compound B2

[0266]

[0267] Diamine 1B (see step 1 of Example 1) (20 g, 71.1 mmol) and Et 3 CH of N (30ml, 213mmol) 2 Cl 2 (400ml) solution was cooled to 0°C in an ice-water bath. To this stirred solution was added triphosgene (14.2 g, 47.3 mmol) in portions carefully (exothermicly!) over 30 minutes. When the addition was complete, stirring was continued at 0°C for 1 hour, then at room temperature for 16 hours. The mixture was washed with 0.5N NaOH (200ml), and the organic layer was washed with anhydrous MgSO 4 Dry and concentrate in vacuo. To the semi-solid residue was added hot EtOAc (200ml) and the resulting mixture was cooled to room temperature. Filtration to obtain compound B2 (16.5g) as a white solid; the filtrate was subjected to silica gel flash chromatography [CH 2 Cl 2 -CH 3 OH(2N NH 3 )=40:1], an additional product (2.7 g) was obtained as a white solid [total yiel...

Embodiment 3

[0278] Preparation of Intermediate Compound C

[0279]

[0280] Synthesis of Step 1 Compound C1

[0281]

[0282] In access N 2 In a flask, NaH (60mg, 60% dispersion; 1.48mmol) was added to CH 3 OH (4ml). After stirring at room temperature for 30 minutes, compound B3 (400 mg, 1.23 mmol) was added, and the resulting mixture was stirred at room temperature for 16 hours. Vacuum removal of CH 3 OH, CH was added to the resulting residue 2 Cl 2 (30ml) and water (10ml). The organic layer was washed with anhydrous MgSO 4 Dry, filter and concentrate in vacuo. The resulting residue was purified using flash chromatography on silica gel, eluting with EtOAc-hexane (3:2), to afford compound C1 (0.232 g; 59%) as a white foam. ES-MS: 322.1 (MH + ; 100%).

[0283] Synthesis of Step 2 Compound C

[0284] 1N Aqueous KOH (4.82ml; 4.82mmol) was added to a solution of compound C1 in EtOH (15ml), and the resulting mixture was stirred at 80°C for 48 hours. The mixture was concentra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to compounds of formula (I); compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IGT) in a patient.

Description

field of invention [0001] The present invention relates to benzimidazole derivatives, compositions comprising said piperidine derivatives, and use of said benzimidazole derivatives to treat or prevent pain, diabetes, diabetic complications, impaired glucose tolerance (IGT) or fasting in patients Methods for Irregular Glucose (IFG). Background of the invention [0002] Diabetes mellitus is a multifactorial disease process characterized by elevated plasma glucose levels, or hyperglycemia following glucose administration in the fasted state or during an oral glucose tolerance test. Persistent or uncontrolled hyperglycemia is associated with increased and earlier timing of morbidity and mortality. Abnormal glucose homeostasis is associated with changes in lipid, lipoprotein, and apolipoprotein metabolism, as well as other metabolic and hemodynamic disorders. Thus, diabetic patients are at high risk of macrovascular and microvascular complications, including coronary heart dise...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/437A61K45/06A61P3/10A61P29/00
CPCA61K31/437A61K45/06A61P29/00A61P3/00A61P3/10A61P3/04A61P43/00A61P9/10A61K2300/00A61K31/4184
Inventor R·G·艾斯兰安J·E·拉克威兹M·Y·柏林J·J·华
Owner SCHERING AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com